Isopropenyl-ethylcarbonat | 63436-79-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Isopropenyl-ethylcarbonat
• 英文别名: carbonic acid ethyl ester-isopropenyl ester；Aethyl-isopropenyl-carbonat；Kohlensaeure-aethyl-isoaceton-ester；Kohlensaeure-aethylester-isopropenylester；ethyl isopropenyl carbonate；ethyl prop-1-en-2-yl carbonate
• CAS: 63436-79-3
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: BGMVLBBDIMNGTP-UHFFFAOYSA-N

物化性质

• 沸点：
  161.0±13.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Isopropenyl-ethylcarbonat 在 盐酸 作用下， 以 乙醚 为溶剂， 以1.1 g的产率得到1-chloro-1-methyl-ethyl ethyl carbonate
  参考文献：
  名称：

  ARYLPROPIONIC ACID DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND APPLICATION THEREOF

  摘要：

  提供了一种由式（I）表示的芳基丙酸衍生物，以及其制备方法和应用的制药组合物。该芳基丙酸衍生物具有良好的半衰期、药物动力学特性和体外稳定性，并且在制备成制剂后可以增强疗效并减少毒性，修复传统非甾体抗炎药常规使用、胃肠道副作用和患者依从性不佳等缺陷。

  公开号：

  US20220274911A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 生成 Isopropenyl-ethylcarbonat
  参考文献：
  名称：

  Bacon; Freer, American Chemical Journal, 1907, vol. 38, p. 367

  摘要：

  DOI：

文献信息

• [EN] 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES<br/>[FR] DERIVES 4-(3,3-DIHALO-ALLYLOXY)PHENOXYALKYLE
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2004002943A1

  公开（公告）日：2004-01-08

  Compounds of formula (I), wherein A1, A2 and A3 are each independently of the others a bond or a C1-C6alkylene bridge; A4 is a C1-C6alkylene bridge; Di s CH or N; W is, for example, O, NR7 or S; T is, for example, a bond, O, NH or NR7; Q is O, NR7, S, SO or SO2; Y is O, NR7, S, SO, or SO2; X1 and X2 are each independently of the other fluorine, chlorine or bromine; R1, R2 and R3 ar, for example, H, halogen, CN, nitro, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylcarbonyl or C2-C6alkenyl; R4 is, for example, H, halogen, CN, nitro or C1-C6alkyl; R5 and R6 are, for example, H, CN, OH, C1-C6alkyl, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C1-C6 haloalky, C1-C6alkoxy or C1-C6haloalkoxy; R7 is H, C1-C6alkyl, C1-C6alkoxyalkyl or C1-C6alkylcarbonyl; k, when D is nitrogen, is 1, 2 or 3; or, when D is CH, is 1, 2, 3 or 4; and m is 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds or an agrochemically acceptable salt thereof, a process for the preparation of those compositions and their use, plant propagation material treated with those compositions, and a method of controlling pests.

  化学式为（I）的化合物，其中A1、A2和A3各自独立地为键或C1-C6烷基桥；A4为C1-C6烷基桥；Di为CH或N；W为例如O、NR7或S；T为例如键、O、NH或NR7；Q为O、NR7、S、SO或SO2；Y为O、NR7、S、SO或SO2；X1和X2各自独立地为氟、氯或溴；R1、R2和R3例如为H、卤素、CN、硝基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷基羰基或C2-C6烯基；R4例如为H、卤素、CN、硝基或C1-C6烷基；R5和R6例如为H、CN、OH、C1-C6烷基、C3-C8环烷基、C3-C8环烷基-C1-C6烷基、C1-C6卤代烷氧基或C1-C6烷氧基；R7为H、C1-C6烷基、C1-C6烷氧基烷基或C1-C6烷基羰基；当D为氮时，k为1、2或3；或当D为CH时，k为1、2、3或4；m为1或2；适用时，它们的可能的E/Z异构体、E/Z异构体混合物和/或互变异构体，均为自由形式或盐形式，制备这些化合物的方法及其用途，所述活性成分被选自这些化合物或其农药学上可接受的盐的杀虫剂组合物，制备这些组合物的方法及其用途，用这些组合物处理的植物繁殖材料，以及控制害虫的方法。
• IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND USE
  申请人：Nanjing Heron Pharmaceutical Science and Technology Co., Ltd.

  公开号：EP3984989A1

  公开（公告）日：2022-04-20

  Provided is an ibuprofen ester prodrug represented by Structural Formula (1), a racemate, stereoisomer or pharmaceutically acceptable salt or solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof. Further provided are a method for preparing the compound, a pharmaceutical composition containing the compound, and an application of the compound in preparation of nonsteroidal anti-inflammatory drugs. The pharmaceutical composition containing the ibuprofen ester prodrug may be prepared into fat emulsion injection preparations. The ibuprofen ester prodrug has good stability and good pharmacokinetic properties and overcomes the problems of ibuprofen such as a short half-life, poor stability, irritation, and incompatibility.

  提供的是一种伊布普洛芬酯前药，其结构式表示为（1），可以是混合物、立体异构体或药学上可接受的盐或溶剂化物，或其药学上可接受的盐的溶剂化物。还提供了一种制备该化合物的方法，包含该化合物的制药组合物，以及该化合物在制备非甾体抗炎药方面的应用。含有伊布普洛芬酯前药的制药组合物可以制备成脂肪乳注射制剂。伊布普洛芬酯前药具有良好的稳定性和良好的药代动力学特性，克服了伊布普洛芬的问题，例如短半衰期、稳定性差、刺激性和不相容性。
• SOLUBLE BRANCHED POLYMERS
  申请人：Grigoras Cristian

  公开号：US20140303313A1

  公开（公告）日：2014-10-09

  Branched polymers are prepared from at least (A) at least one monomer having an electron donor moiety, (B) at least one monomer having an electron acceptor moiety, and (C) at least one multifunctional branching agent comprising a urea moiety and at least two N-vinyl groups. The branched polymers are least 20% (by weight) soluble in a solvent for which the corresponding polymer of equal molecular weight made without said multifunctional branching agent is at least 20% (by weight) soluble. Due in part to the wide range of chemistries and solubility and rheological properties, the branched polymers find application in personal care, pharmaceutical/nutritional, and performance chemicals compositions.

  分支聚合物由至少（A）至少一种具有电子给体基团的单体，（B）至少一种具有电子受体基团的单体和（C）至少一种多功能分支剂组成，该分支剂包含尿素基团和至少两个N-乙烯基团。这些分支聚合物在相应的等分子量聚合物不含多功能分支剂的溶剂中至少有20％（重量）的溶解度，由于其广泛的化学性质、溶解度和流变性质，这些分支聚合物在个人护理、制药/营养和性能化学成分中应用广泛。
• ARYLPROPIONIC ACID DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD.

  公开号：US20220274911A1

  公开（公告）日：2022-09-01

  Provided are an arylpropionic acid derivative represented by Formula (I), a pharmaceutical composition and a preparation method and an application thereof. The arylpropionic acid derivative has a good half-life, pharmacokinetic property and in vitro stability and can enhance efficacy and reduce toxicity after formulated into preparations, which repairs the defects of frequent administration, gastrointestinal side effects and poor patient compliance of traditional nonsteroidal anti-inflammatory drugs.

  提供了一种由式（I）表示的芳基丙酸衍生物，以及其制备方法和应用的制药组合物。该芳基丙酸衍生物具有良好的半衰期、药物动力学特性和体外稳定性，并且在制备成制剂后可以增强疗效并减少毒性，修复传统非甾体抗炎药常规使用、胃肠道副作用和患者依从性不佳等缺陷。
• HYDROGEL COMPOSITION AND HYDROGEL CONTACT LENSES MADE OF THE COMPOSITION
  申请人：Pegavision Corporation

  公开号：EP3173826A1

  公开（公告）日：2017-05-31

  A hydrogel composition and a hydrogel contact lens made of the hydrogel composition are provided. The hydrogel composition includes a hydrophilic monomer, a blue light-blocking monomer, a crosslinker and an initiator. The hydrophilic monomer is in a range from 30 to 99.68 parts by weight. The blue light-blocking monomer is in a range from 0.02 to 0.5 parts by weight and has a yellow dye. The crosslinker is in a range from 0.1 to 1 parts by weight. The initiator is in a range from 0.2 to 2 parts by weight.

  本发明提供了一种水凝胶组合物和由该水凝胶组合物制成的水凝胶隐形眼镜。 水凝胶组合物包括亲水单体、阻蓝光单体、交联剂和引发剂。 亲水单体的重量范围为 30 至 99.68 份。 蓝色阻光单体的重量范围为 0.02 至 0.5 份，具有黄色染料。 交联剂的重量范围为 0.1 至 1 份。 引发剂的重量范围为 0.2 至 2 份。